Is left ventricular hypertrophy regression important? Does the tool used to detect it matter?

Journal of Clinical Hypertension

Volumn 11, Issue 8, 2009, Pages 441-447

  Nadour, Wadih ^a   Biederman, Robert W W ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LOSARTAN; RAMIPRIL; TELMISARTAN;

BLOOD PRESSURE REGULATION; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; RISK FACTORS; TREATMENT OUTCOME;

EID: 69049092894     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00137.x     Document Type: Review

References (43)

1. Carini G, Circo A, Dovellini E. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol. 2001;38:1829-1835.
2. Drazner MH, Rame JE, Marino EK, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: The cardiovascular health study. J Am Coll Cardiol. 2004;43:2207-2215.
3. Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-2044.
4. Levy D, Garrison R, Savage D, et al. Prognostic implications of echocariographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
5. Ghali J, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831-836.
6. Kaplinsky E. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther. 1994;8:549-556.
7. Kannel W, Cobb J. Left ventricular hypertrophy and mortality: Results from the Framingham study. Cardiology. 1992;81:291-298.
8. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
9. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
10. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349.
11. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass during treatment of hypertension. JAMA. 2004;292:2350-2356.
12. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275:19.
13. Gottdiener SJ, Reda JD, Massie MB, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation. 1997;95:2007-2014.
14. Liebson RP, Grandits AG, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation. 1995;91:698-706.
15. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-LEFT ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
16. Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass. Am J Hypertens. 2005;18:1563-1569.
17. Murphy ML, Thenabadu PN, deSoyza N, et al. Sensitivity of electrocardiographic criteria for left ventricular hypertrophy according to type of cardiac disease. Am J Cardiol. 1985;55:545-549.
18. Casale PN, Devereux RB, Kligfield P, et al. Electrocardiographic detection of left ventricular hypertrophy: Development and prospective validation of improved criteria. J Am Coll Cardiol. 1985;6:572-580.
19. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens. 1998;16:715-723.
20. Missouris CG, Forbat SM, Singer DR, et al. Echocardiography overestimates left ventricular mass: A comparative study with magnetic resonance imaging in patients with hypertension. J Hypertens. 1996;14:1005-1010.
21. Myerson SG, Montgomery HE, World MJ, et al. Left ventricle mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension. 2002;40:673-678.
22. Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MR imaging. Radiology. 1988;169:495-498.
23. Florentine MS, Grosskreutz CL, Chang W, et al. Measurement of left ventricular mass in vivo using gated nuclear magnetic resonance imaging. J Am Coll Cardiol. 1986;8:107-112.
24. Germain P, Roul G, Kastler B, et al. Inter-study variability in left ventricular mass measurement. Comparison between M-mode echocardiography and MRI. Eur Heart J. 1992;13:1011-1019.
25. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995;8:221-228.
26. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. BMJ. 1985;291:97-104.
27. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment of hypertension. Hypertension. 1989;13:136-144.
28. Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke, and coronary heart disease, Part 2: Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
29. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
30. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long term antihypertensive treatment. J Hypertens. 1995;13:1091-1095.
31. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
32. Hypertension Detection and Follow up-Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105-112.
33. MacMahon S, Collins G, Rautaharju P, et al. Electrocardiographic left ventricular hypertrophy and the effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989;63:202-210.
34. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE Substudy. Hypertension. 2001;38:E28-E32.
35. Gonzalez-Fernandez RA, Rivera M, Rondriguez PJ, et al. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens. 1993;6:308-313.
36. Rials SJ, WU Y, XU X, et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation. 1997;96:1330-1336.
37. Okin PM, Devereux RB, Harris KE, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147:311-319.
38. Mayet J, Ariff B, Wasan B, et al. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. Hypertension. 2000;36:755-759.
39. Biederman RW, Doyle M, Young AA, et al. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients. A losartan intervention for endpoint reduction in hypertension (LIFE) Cardiovascular Magnetic Resonance and Echocardiographic Substudy. Hypertension. 2008;52:279-286.
40. Klingbeil AU, Schneider M, Martus P, et al. A meta analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
41. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol. 2004;15:1640-1647.
42. Okin PM, Devereux RB, Gerdts E, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy. The losartan intervention for endpoint reduction in hypertension study. Circulation. 2006;113:1588-1596.
43. Nadour W, Biederman RWW. Hypertensive left ventricular hypertrophy regression; does it matter? Curr Hypertens Rev. 2008;4(3):275-288.